ENTEREG
Peakalvimopan
NDAORALCAPSULE
Approved
May 2008
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
16
Mechanism of Action
μ-opioid receptor with a Ki of 0.4 nM (0.2 ng/mL) and no measurable opioid-agonist effects in standard pharmacologic assays. The dissociation of [H]-alvimopan from the human μ-opioid receptor is slower than that of other opioid ligands, consistent with its higher affinity for the receptor. At…
Clinical Trials (5)
Alvimopan Versus Placebo in Patients Undergoing Radical Cystectomy on an Enhanced Recovery Protocol
Started Oct 2018
136 enrolled
Bladder Cancer
Alvimopan Use in Polytraumatized Patients
Started Sep 2017
3 enrolled
Post Operative Ileus
Trial of Alvimopan in Major Spine Surgery
Started Jun 2016
49 enrolled
Constipation
Alvimopan as Rescue in Post op Ileus
Started Dec 2015
14 enrolled
Colorectal SurgeryIleus
Entereg Laparoscopic Colon Resection Study
Started Nov 2010
Laparoscopic Colonic Resection
Loss of Exclusivity
LOE Date
Feb 12, 2030
48 months away
Patent Expiry
Feb 12, 2030
Patent Records (1)
| Patent # | Expiry | Type | Use Code |
|---|---|---|---|
| 8946262 | Feb 12, 2030 | U-1655 |